Stereotaxis

Stereotaxis

Stereotaxis was founded in 1990 and went public in 2004, building its business around the Niobe magnetic navigation system, which uses precisely controlled magnetic fields to guide catheters and guidewires through the heart during minimally invasive procedures. The company has historically generated revenue from selling its robotic systems, disposable components, and service contracts, primarily to electrophysiology labs treating cardiac arrhythmias. David Fischel took over as CEO in 2017 after a proxy contest, and the company has since emphasized a strategic shift toward recurring revenue by driving higher procedure volumes on its installed base — a model more akin to Medtronic's service-oriented cardiology lines than to Intuitive Surgical's capital-heavy da Vinci placements. Stereotaxis operates in the surgical robotics niche, specifically within interventional cardiology and electrophysiology. Its core product, the Genesis RMN system, represents the latest generation of robotic magnetic navigation, offering smaller footprint, faster setup, and improved workflow compared to prior versions. The company does not sell broad-surgical robots for general or orthopedic surgery; its focus remains exclusively on catheter-based cardiac procedures, primarily atrial fibrillation ablation and ventricular tachycardia mapping. This concentrated addressable market means Stereotaxis' growth relies on demonstrating superior procedural outcomes, reducing radiation exposure for physicians, and expanding adoption within an oligopoly of dominant electrophysiology equipment makers, including Abbott, Johnson & Johnson's Biosense Webster, and Boston Scientific. The company has pursued adjacent partnerships, including a robotic guidewire development agreement with MicroPort EP. As a publicly traded micro-cap (NYSE: STXS), Stereotaxis reports its financials quarterly. The firm employs fewer than 150 people and maintains its headquarters in St. Louis, Missouri. It has operated without a permanent CFO for extended periods, including a vacancy filled in 2023 with the appointment of a new finance chief. Revenue has historically been lumpy, tied to system sales cycles; the company's articulated strategy hinges on converting to a high-margin, recurring-revenue stream from disposables and service agreements on a growing base of ~150 installed systems globally. In recent years, Stereotaxis has reported gradual sequential growth in system utilization and recurring revenue, though profitability has remained elusive. Unlike most surgical-robotics companies, Stereotaxis does not compete on multi-port, soft-tissue versatility but on a specific niche advantage: its magnetic navigation eliminates the mechanical torque of manual catheters, enabling precise steering in complex anatomies where standard approaches fail. This gives the company a defensible but narrow moat, reliant on physician conviction that the clinical benefit of magnetic navigation justifies the cost and workflow change. The company's future depends less on launching a general-purpose robot and more on proving that its installed base can support sustained, high-margin recurring revenue through increased procedure volumes and disposable sales.